Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients —sequentially, or better simultaneously?

ConclusionRegarding oncologic outcome, the influence of sequencing radiation therapy with maintenance capecitabine chemotherapy in the post-neoadjuvant setting is unclear. Synchronous administration of capecitabine is feasible, but reports on possible excess toxicities are partially conflicting. Dose reduction of capecitabine should be considered, especially if normofractionated radiotherapy is used. In terms of tolerance, hypofractionated schedules seem to be superior in terms of toxicity in concurrent settings. T ‑DM1 can safely be administered concurrently with radiotherapy.

Source: Strahlentherapie und Onkologie - July 30, 2020 Category: Cancer & Oncology Source Type: research